[go: up one dir, main page]

WO2022173247A2 - Composition contenant un extrait de chlorella sp. et une fraction phéophytinisée de celui-ci ou composé à base de porphyrine ou de caroténone obtenu à partir de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie du coronavirus-19 - Google Patents

Composition contenant un extrait de chlorella sp. et une fraction phéophytinisée de celui-ci ou composé à base de porphyrine ou de caroténone obtenu à partir de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie du coronavirus-19 Download PDF

Info

Publication number
WO2022173247A2
WO2022173247A2 PCT/KR2022/002046 KR2022002046W WO2022173247A2 WO 2022173247 A2 WO2022173247 A2 WO 2022173247A2 KR 2022002046 W KR2022002046 W KR 2022002046W WO 2022173247 A2 WO2022173247 A2 WO 2022173247A2
Authority
WO
WIPO (PCT)
Prior art keywords
chlorella
extract
fraction
preventing
carotenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/002046
Other languages
English (en)
Korean (ko)
Other versions
WO2022173247A3 (fr
Inventor
오원근
이바울
초효문
폰스호르헤
최영기
김은하
김세미
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Chungbuk National Univiversity CBNU
Original Assignee
Seoul National University R&DB Foundation
Chungbuk National Univiversity CBNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University R&DB Foundation, Chungbuk National Univiversity CBNU filed Critical Seoul National University R&DB Foundation
Publication of WO2022173247A2 publication Critical patent/WO2022173247A2/fr
Publication of WO2022173247A3 publication Critical patent/WO2022173247A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N35/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
    • A01N35/04—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aldehyde or keto groups, or thio analogues thereof, directly attached to an aromatic ring system, e.g. acetophenone; Derivatives thereof, e.g. acetals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/03—Algae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/202—Algae extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Definitions

  • An object of the present invention is to provide a composition for preventing or treating novel coronavirus infection, comprising, as an active ingredient, a Chlorella sp. extract or a pheophytinated fraction thereof or a polphyrin-based or carotenone-based compound isolated therefrom there is
  • Another object of the present invention is to provide a disinfectant for preventing new coronavirus infection comprising Chlorella sp. extract or a pheophytinated fraction thereof or a polphyrin-based or carotenone-based compound isolated therefrom as an active ingredient. have.
  • the chlorella extract may be obtained by extracting Chlorella sp. powder with any one solvent selected from the group consisting of water, C1 to C4 lower alcohols, hexane, acetone, methylene chloride, ethyl acetate, and mixed solvents thereof.
  • the chlorella extract may be an extract obtained by extracting chlorella with 70-100% C1 to C4 aqueous solution of lower alcohol or lower alcohol or acetone, or a hexane fraction obtained by pheophytinizing these hexane fractions and extracts.
  • the compound included in the chlorella extract can be obtained by separating the hexane fraction of the extract obtained by extracting chlorella with 70-100% C1 to C4 aqueous solution or lower alcohol or acetone and the hexane fraction obtained by pheophytinizing the extract, preferably can be obtained by separating an extract extracted with 100% methanol or 95% ethanol or a hexane fraction obtained by pheophytinizing the extract by chromatography.
  • Chlorella sp. extract of the present invention is obtained by extracting chlorella powder with any one solvent selected from the group consisting of water, C1 to C4 lower alcohols, hexane, acetone, methylene chloride, ethyl acetate, and mixed solvents thereof, respectively.
  • the pheophytination fraction of the Chlorella sp. extract of the present invention contains 0.05 to 10% (w/v) of the Chlorella extract. After being suspended in an aqueous citric acid solution of , it may be extracted with any one solvent selected from the group consisting of hexane, methylene chloride, ethyl acetate, and a mixed solvent thereof.
  • composition for preventing or treating novel coronavirus infection of the present invention includes pheophytin A (Compound 1), pheophytin B (Compound 2), alpha-apo-13-carotenone (Compound 3) and beta -Apo-13-carotenone (Compound 4) may include one or more from the group consisting of.
  • the chlorella extract and the pheophytinated hexane fraction or the pharmaceutical composition comprising the polphyrin-based or carotenone-based compound isolated therefrom, respectively, are prepared in powders, granules, tablets, capsules, suspensions, emulsions, syrups, It can be used in the form of oral dosage forms such as aerosols, external preparations, suppositories, and sterile injection solutions.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations include the chlorella extract and pheophytinated hexane fraction of the present invention, or a polphyrin-based or carotenone-based preparation separated therefrom.
  • the compound is prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like.
  • Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • the dosage of the composition will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathology, the route of administration, and the judgment of the prescriber. Dosage determination based on these factors is within the level of one of ordinary skill in the art, and generally dosages range from 0.01 mg/kg/day to approximately 2000 mg/kg/day. A more preferred dosage is 0.1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
  • the pharmaceutical composition may be administered to mammals such as mice, livestock, and humans by various routes.
  • the present invention provides a health functional food for preventing or improving novel coronavirus infection, comprising, as an active ingredient, a Chlorella sp. extract or a pheophytinated fraction thereof or a polphyrin-based or carotenone-based compound isolated therefrom. .
  • the Chlorella ( Chlorella sp.) extract may be obtained by extracting chlorella powder with any one solvent selected from the group consisting of water, C1 to C4 lower alcohols, hexane, acetone, methylene chloride, ethyl acetate, and mixed solvents thereof. .
  • the pheophytinated fraction of the Chlorella ( Chlorella sp.) extract is suspended in 0.5 to 1.0 N hydrochloric acid aqueous solution, or 0.05 to 10% (w/v) citric acid aqueous solution, or suspended in water. After drying, it may be left at 60° C. for 30 minutes to 48 hours, and then extracted with any one solvent selected from the group consisting of hexane, methylene chloride, ethyl acetate, and mixed solvents thereof.
  • the health functional food for preventing or improving the novel coronavirus infection is pheophytin A (compound 1), pheophytin B (compound 2), alpha-apo-13-carotenone (compound 3) and beta-apo-13 - Carotenone (Compound 4) may include one or more from the group consisting of.
  • the present invention provides a disinfectant for preventing new corona virus infection, comprising, as an active ingredient, a Chlorella sp. extract or a pheophytinated fraction thereof, or a polphyrin-based or carotenone-based compound isolated therefrom.
  • the antiseptics for preventing novel coronavirus infection are pheophytin A (Compound 1), pheophytin B (Compound 2), alpha-apo-13-carotenone (Compound 3) and beta-apo-13-carotenone (Compound 4).
  • pheophytin A Compound 1
  • pheophytin B Compound 2
  • alpha-apo-13-carotenone Compound 3
  • beta-apo-13-carotenone Compound 4
  • the present invention provides an animal drug for the prevention or treatment of new coronavirus infection, or animal feed additive for preventing or improving new coronavirus infection, comprising a mixture according to the components of Chlorella sp. extract and a combination thereof as an active ingredient provides
  • Chlorella Chlorella sp. extract and pheophytination fraction or polphyrin-based or carotenone-based compounds isolated therefrom, which show cell lesion recovery ability against novel coronavirus infection according to the present invention, are produced in animals and humans. It is expected to be useful as a medicine for the prevention or treatment of infection.
  • the pheophytinized fraction or the polphyrin-based compound isolated therefrom can be prepared from chlorophyll, a green plant, and can be usefully used as a pharmaceutical for preventing or treating new corona infection in animals and humans.
  • 1 is a chromatogram showing the presence or absence and relative content of polphyrin-based or carotenone-based compounds in each fraction including Chlorella sp. extract.
  • Chlorella sp. Chlorella sp.
  • SARS-CoV-2 novel coronavirus
  • FIG. 3 is a graph showing the increased ability to recover from cell lesions against novel coronavirus (SARS-CoV-2) infection through mixing of Chlorella sp. extract fractions.
  • SARS-CoV-2 novel coronavirus
  • Figure 6 is a chromatogram showing the relative content change of pheophytin A and B by (A) pheophytinylation of the Chlorella sp. extract by varying the concentration of the mineral acid and (B) the extract containing the pheophytinized fraction and It is a chromatogram showing the presence or absence of apo-13-carotenone-based compounds, which are active substances, in the fraction.
  • FIG. 7 is a chromatogram showing the relative content change of pheophytin A and B by pheophytinizing the Chlorella sp. extract by varying the concentration of organic acid.
  • FIG. 8 is a chromatogram showing the relative content changes of pheophytin A and B by pheophytinizing the Chlorella sp. extract by varying the heating treatment time.
  • FIG. 9 is a chromatogram showing the relative content change of pheophytin A and B by pheophytinizing the spinach ( Spinacia oleracea ) extract by varying the concentration of inorganic acid.
  • Chlorella sp. 10 is a Chlorella ( Chlorella sp.) extract, a pheophytinated fraction containing a polphyrin-based and carotenone-based compound, and a mixture of pheophytin A and B.
  • SARS-CoV-2 novel coronavirus
  • the present inventors are conducting research to discover natural candidate natural extracts with pharmacological activity against novel coronavirus for natural extracts of the Bioactive Material Resource Bank, starting by confirming that the extract of Chlorella has an excellent antiviral effect.
  • the present invention was completed by identifying active substances and their synergistic combinations through bioactivity-guided fractionation and isolation and maximizing the content of active substances.
  • Chlorella ( Chlorella sp.) powder was purchased from a commercial company and extracted three times by stirring to minimize chlorophyll destruction using 100 g of 95% ethanol. After drying the extract, 2.1 g of a crude extract was obtained. Thereafter, the following conditions (solvent: EA/MeOH/H) were used using medium pressure liquid chromatography (MPLC) to identify the active material by bioactivity-guided fractionation and isolation.
  • solvent EA/MeOH/H
  • chlorophyll a In addition to 9 small fractions including the obtained extract, in the subsequent experiment, chlorophyll b, sodium copper chlorophyll, and beta-carotene were purchased from Sigma-Aldrich as single substances among chlorella-derived substances and their inhibitory ability against SARS-CoV-2 was tested. measured together.
  • Cytopathic effect (CPE) assay was performed to confirm the effect of the chlorella extract and fractions of the present invention on the proliferation of coronavirus.
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, NMC-CoV-02 strain
  • SARS-CoV-2 virus was inoculated into mono-layered VERO cells, and virus culture supernatant was collected 3 days later, and the virus was inoculated into VERO cells cultured in DMEM medium containing 10% [v/v] FBS. and was used to measure antiviral activity.
  • Example 2-1 After the SARS-CoV-2 virus prepared in Example 2-1 was infected with VERO cells, the extracts and fractions prepared in Example 1 were treated to perform a CPE assay.
  • VERO cells were seeded in a 96-well plate at a density of 2 ⁇ 10 4 cells/well, and 10% [v/v] FBS (fetal bovine serum), 1% [v/v] PS (penicillin+streptomycin) And L-glutamine (L-glutamine, 2ml added based on 500ml medium) was grown for one day in DMEM culture medium, and then the culture medium was washed with PBS solution.
  • FBS fetal bovine serum
  • PS penicillin+streptomycin
  • L-glutamine L-glutamine, 2ml added based on 500ml medium
  • each of the extracts and fractions of the present invention were treated by concentration, and cultured for 3 days in a DMEM culture medium containing (infection media: DMEM+0.2 ⁇ g/ml trypsin), and the effect on the virus was measured. After 3 days of culture, the effect of CPE was checked according to the concentration of extracts and fractions to measure the viability of VERO cells. The results of measuring virus titers according to the concentrations of extracts and fractions are shown in FIG. 2 .
  • fractions 1 (C1), 7 (C7) and 8 (C8) of the fractions obtained by fractionation from chlorella showed a proliferation inhibitory effect on SARS-CoV-2.
  • C1 is a complex
  • C7 and C8 are parts containing pheophytin B and A as main compounds, respectively.
  • the C2 and C3 fractions containing carotenoid compounds as main compounds did not show inhibitory activity
  • Example 3 Based on the results of Example 3, in order to identify a substance exhibiting a synergistic effect from C1, the variable of the combination was fixed to C7, which showed the second strongest inhibitory ability, except for C1, and a small fraction of C1 (C1.1 - C1. 8) and the synergistic effect was confirmed.
  • the results are shown in FIG. 5 .
  • C1.6 and C1.7 showed the strongest effect among single subfractions. Through this, it can be expected that substances involved in the activity are included in C1.6 and C1.7, and when referring to FIG. 4 of Example 4, C1.6 and C1.7 include substances of the same series. It could be predicted through the UV pattern.
  • C1.6 showed the strongest synergistic effect. However, since it was confirmed through additional experiments that C1.6 is particularly unstable to heat and deforms into another form, an experiment was started to separate the active material from the relatively stable C1.7.
  • alpha-apo-13-carotenone (Compound 3) or beta-apo-13-carotenone (Compound 4), which are pheophytin A, pheophytin B, and apo-13-carotenone-based compounds in the chlorella extract according to the above results ) showed inhibitory activity against SARS-CoV-2, and it was confirmed that a mixture thereof exhibited synergistically excellent antiviral activity against SARS-CoV-2.
  • Example 8-1 Preparation of pheophytinated fractions using inorganic acids
  • the chlorella powder was stirred with 95% ethanol and extracted using the extract, and the conditions of the aqueous hydrochloric acid solution were changed to 0.1 N, 0.5 N, and 1 N, and pheophytination was performed.
  • Example 8-2 Preparation of pheophytinated fractions using organic acids
  • Hamsters of all groups were challenged with SARS-CoV-2 (NMC-CoV-02) virus at a dose of 10 4.0 TCID 50 through the nasal cavity, and 0.5 compound was administered once (every 24 hours) at the same time every day from the day of challenge inoculation. mL each was orally administered.
  • virus titers were measured in nasal and lung tissues of hamsters. The virus titer results in each tissue are shown in FIG. 10 .
  • the chlorella extract (7dpi: 2.0log 10 TCID 50 /g) group both confirmed the result of significantly lowering the virus titer on the 7th day of challenge inoculation.
  • the chlorella extract or the mixture of pheophytin A and B has strong antiviral activity against SARS-CoV-2, and the pheophytinized fraction has a higher antiviral activity than the chlorella extract or the mixture of pheophytin A and B. It was found to exhibit viral activity.
  • substances other than pheophytin A and B contained in the pheophytinized fraction for example, carotenone derivatives such as apo-13-carotenone-based compounds, are included through carotenone derivatives. It can be inferred that it has a strong antiviral activity by synergizing with pheophytin A and B.
  • 20 g of the chlorella extract (or pheophytinated fraction) of the present invention or pheophytin A, pheophytin B, 200 mg of at least one selected from the group consisting of alpha-apo-13-carotenone and beta-apo-13-carotenone was mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicic acid, respectively. After adding a 10% gelatin solution to this mixture, it was ground and passed through a 14 mesh sieve. This was dried, and 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate were added thereto, and the resulting mixture was made into tablets.
  • Pheophytin A, pheophytin B of the present invention 100 mg of at least one selected from the group consisting of alpha-apo-13-carotenone and beta-apo-13-carotenone, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 ml. This solution was placed in a bottle and sterilized by heating at 20 °C for 30 minutes.
  • Chlorella extract of the present invention (or pheophytinized fraction) or pheophytin A, pheophytin B, At least one selected from the group consisting of alpha-apo-13-carotenone and beta-apo-13-carotenone was added to each cooking seasoning in an amount of 1% by weight to prepare a cooking seasoning for health promotion.
  • Chlorella extract of the present invention (or pheophytinized fraction) or pheophytin A, pheophytin B, At least one selected from the group consisting of alpha-apo-13-carotenone and beta-apo-13-carotenone is each added in an amount of 0.1% by weight to wheat flour, and the mixture is used to produce bread, cakes, cookies, crackers and Foods for health promotion were prepared by manufacturing noodles.
  • Chlorella extract of the present invention (or pheophytinized fraction) or pheophytin A, pheophytin B, At least one 2 selected from the group consisting of alpha-apo-13-carotenone and beta-apo-13-carotenone was added to the broth in an amount of 0.1% by weight, respectively, to prepare a health-improving soup and broth.
  • Chlorella extract of the present invention (or pheophytinized fraction) or pheophytin A, pheophytin B, At least one member selected from the group consisting of alpha-apo-13-carotenone and beta-apo-13-carotenone is added to each milk in an amount of 0.1% by weight, and various dairy products such as butter and ice cream are prepared using the milk. prepared.
  • 20 g of the chlorella extract (or pheophytinated fraction) of the present invention or pheophytin A, pheophytin B, A vegetable juice for health promotion was prepared by adding 200 mg of at least one selected from the group consisting of alpha-apo-13-carotenone and beta-apo-13-carotenone to 1,000 ml of tomato juice or sugar root juice, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Pest Control & Pesticides (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition contenant un extrait de Chlorella sp. et une fraction phéophytinisée ou un composé à base de porphyrine ou de caroténone isolé à partir de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie du coronavirus-19. La composition présente une teneur accrue en composés à base de porphyrine, la phéophytine A (composé 1) et la phénophytine B (composé 2) qui sont des composés actifs, par l'intermédiaire d'un procédé chimique et contient en outre un composé à base de caroténone, trouvant ainsi des applications avantageuses, en particulier dans le traitement et la prévention d'une maladie du coronavirus-19 chez l'homme par son activité antivirale synergique.
PCT/KR2022/002046 2021-02-10 2022-02-10 Composition contenant un extrait de chlorella sp. et une fraction phéophytinisée de celui-ci ou composé à base de porphyrine ou de caroténone obtenu à partir de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie du coronavirus-19 Ceased WO2022173247A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210019462A KR102583001B1 (ko) 2021-02-10 2021-02-10 클로렐라(Chlorella sp.)추출물 및 이의 페오피틴화 분획물 또는 이로부터 수득한 폴피린계 또는 카로테논계 화합물을 유효성분으로 포함하는 신종코로나 바이러스 감염의 예방 또는 치료용 조성물
KR10-2021-0019462 2021-02-10

Publications (2)

Publication Number Publication Date
WO2022173247A2 true WO2022173247A2 (fr) 2022-08-18
WO2022173247A3 WO2022173247A3 (fr) 2022-10-06

Family

ID=82838213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/002046 Ceased WO2022173247A2 (fr) 2021-02-10 2022-02-10 Composition contenant un extrait de chlorella sp. et une fraction phéophytinisée de celui-ci ou composé à base de porphyrine ou de caroténone obtenu à partir de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie du coronavirus-19

Country Status (2)

Country Link
KR (1) KR102583001B1 (fr)
WO (1) WO2022173247A2 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11322753A (ja) * 1998-05-08 1999-11-24 Masaki Kamata 新規な活性フェオフィチン化合物、その製造法及び用途
NZ585620A (en) * 2007-10-26 2013-03-28 Ca Nat Research Council Compositions and methods for enhancing immune response
JP2016065037A (ja) * 2014-09-17 2016-04-28 株式会社日健総本社 抗ウイルス剤の製法及び該製法によって得られた抗ウイルス剤
JP2017160180A (ja) * 2016-03-04 2017-09-14 株式会社ユーグレナ 抗ウイルス剤及び抗ウイルス用食品
KR102176525B1 (ko) 2018-11-07 2020-11-10 한국과학기술원 희생층을 이용한 계층적 주름 구조체의 제조방법 및 이로부터 제조된 계층적 주름 구조체
KR102169476B1 (ko) 2020-05-20 2020-10-23 (주)신테카바이오 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
KR20200131784A (ko) 2020-11-04 2020-11-24 (주)신테카바이오 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2022173247A3 (fr) 2022-10-06
KR20220115759A (ko) 2022-08-18
KR102583001B1 (ko) 2023-09-27

Similar Documents

Publication Publication Date Title
US7732458B2 (en) Methods for preparing dehydrocavidine, dehydroapocavidine or their composition, their use and medicinal composition containing them
KR101406201B1 (ko) 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
WO2010140734A1 (fr) Composition, pour la prévention ou le traitement d'affections liées à l'obésité et médiées par l'activation d'ampk, et dont les principes actifs dont des lignanes de 2,5-bis-aryl-3,4-diméthyltétrahydrofurane
WO2022050516A1 (fr) Agent thérapeutique contre le coronavirus comprenant un extrait d'elaeocarpus sylvestris en tant que principe actif
KR101334143B1 (ko) 폴리갈라 카렌시움 추출물 및 이로부터 분리된 잔톤계 화합물을 함유하는 감기, 조류 인플루엔자, 돼지 인플루엔자 또는 신종플루의 예방 또는 치료용 조성물
KR100720151B1 (ko) 항바이러스 활성을 갖는 플라보노이드 화합물
WO2013105693A1 (fr) Composition pharmaceutique comprenant un extrait de cortex d'oryza sativa l. et d'hordeum vulgare var. hexastichon comme principe actif
WO2022131639A1 (fr) Composition pour inhiber le virus de la grippe, contenant des produits fermentés d'extrait végétal comprenant de la nodakénine ou de la nodakénetine, ou des fractions de ces derniers
WO2013062247A2 (fr) Composé diterpène de type phorbol, et composition pharmaceutique pour le traitement ou la prévention de maladies infectieuses virales le comprenant
WO2011122879A2 (fr) Composition comprenant du coumestrol ou extrait de haricot contenant du coumestrol
EP2535056A2 (fr) Composition de prévention ou de traitement de l'infection à rotavirus, contenant un extrait de réglisse
WO2014116013A1 (fr) Composition pour le traitement, la prévention ou le soulagement de la dégénérescence maculaire, contenant un composé phénolique séparé de vaccinium uliginosum extrait en tant que substance active
KR101427096B1 (ko) 관중 추출물 또는 이로부터 분리된 플로로글루시놀 유도체를 함유하는 코로나 바이러스 관련 질환의 예방 또는 치료용 조성물
WO2022173247A2 (fr) Composition contenant un extrait de chlorella sp. et une fraction phéophytinisée de celui-ci ou composé à base de porphyrine ou de caroténone obtenu à partir de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie du coronavirus-19
KR102038054B1 (ko) 인돌로테르페노이드 화합물, 이의 생산 방법 및 용도
WO2018088777A1 (fr) Composition pour la prévention ou le traitement de la grippe, contenant, en tant que substance active, un extrait d'ecklonia cava ou un composé à base de tannin isolé à partir de celui-ci
WO2023249392A1 (fr) Composition pour la prévention, l'atténuation ou le traitement d'une infection à coronavirus, contenant un extrait d'herbe médicinale utilisé en tant que principe actif
WO2023249393A1 (fr) Composition pour la prévention, l'atténuation ou le traitement d'une infection à coronavirus, contenant un extrait d'herbe médicinale utilisé en tant que principe actif
WO2015065059A1 (fr) Composition pour prévenir ou traiter une septicémie hémorragique virale chez les poissons comprenant un extrait d'ecklonia cava
KR102804041B1 (ko) 구아바(Psidiuma guajava) 잎 추출물 또는 이의 분획물로부터 수득한 세스퀴테르페노이드계 화합물을 유효성분으로 포함하는 신종코로나 바이러스 감염증의 예방 또는 치료용 조성물
WO2022173246A2 (fr) Composition pour la prévention ou le traitement d'une infection par le nouveau coronavirus, comprenant un extrait de psidiuma guajava, une fraction de phéophytine de celui-ci, ou un composé à base de méroterpénoïde isolé à partir de celui-ci en tant que principe actif
WO2012173392A2 (fr) Complexe contenant du stévioside/composé à base de curcuminoïde pour la prévention et le traitement d'une infection par le virus de la grippe
KR102900695B1 (ko) 구아바(Psidiuma guajava) 추출물 또는 이의 페오피틴화 분획물 또는 이로부터 분리한 메로테르페노이드계 화합물을 유효성분으로 포함하는 신종코로나 바이러스 감염의 예방 또는 치료용 조성물
KR102818485B1 (ko) 한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물
WO2025258750A1 (fr) Agent antiviral comprenant un extrait d'ecklonia cava ou de phlorotanins en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22753007

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22753007

Country of ref document: EP

Kind code of ref document: A2